Centering discussion on several patient cases, expert oncologists review key data updates in the multiple myeloma treatment landscape from IMS 2022 and other recent meetings.
EP. 1: Patient Case 1: A 54-Year-Old Woman With Transplant-Eligible NDMM
Opening their discussion on the first patient case, expert panelists review the management of transplant-eligible newly diagnosed multiple myeloma.
EP. 2: Induction Regimens in Transplant-Eligible NDMM: Clinical Trial Data
Comprehensive insight on mainstay induction therapy options for patients with transplant-eligible newly diagnosed multiple myeloma in the context of recent clinical studies.
EP. 3: What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?
A brief review of the role of transplant in patients with newly diagnosed multiple myeloma and how it can be best coupled with systemic treatment.
EP. 4: Post-Transplant Therapy in NDMM: Consolidation and Maintenance Therapy
Expert hematologist-oncologists consider the role of maintenance and consolidation following the completion of transplant in patients with newly diagnosed multiple myeloma.
EP. 5: Patient Case 2: A 79-Year-Old Woman With Transplant-Ineligible NDMM
Switching their attention to the transplant-ineligible setting of newly diagnosed multiple myeloma, panelists center discussion around their second patient case.
EP. 6: Induction Therapy Options for Patients With Transplant-Ineligible NDMM
Expert perspectives on cornerstone induction therapy regimens used in patients with transplant-ineligible newly diagnosed multiple myeloma.
EP. 7: Transplant-Ineligible NDMM: Optimizing Selection and Duration of Therapy
Practical perspectives on the optimal selection of therapy for transplant-ineligible NDMM, followed by considerations for duration of therapy and dosing.
EP. 8: Treating High-Risk Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Before closing out their module on transplant-ineligible newly diagnosed multiple myeloma, panelists reflect on best treatment practices in the setting of high-risk disease.
EP. 9: Patient Case 3: A 65-Year-Old Woman With Relapsed Multiple Myeloma
After reviewing their third patient case, expert hematologist-oncologists highlight the treatment armamentarium for relapsed/refractory multiple myeloma.
EP. 10: Practical Factors in Selecting Therapy for Relapsed/Refractory MM
Shared insight on key factors that determine the best selection of therapy in patients with relapsed/refractory multiple myeloma, with a focus on bispecific antibodies and CAR T-cell therapy.
EP. 11: Future Directions: Novel Targeted Therapies in Multiple Myeloma
A comprehensive review of novel therapy being investigated in the setting of relapsed/refractory multiple myeloma to expand the bispecific antibody and CAR T-cell therapy armamentarium.
EP. 12: Multiple Myeloma Management: Addressing Disparities in Care
Before closing out their review on the management of multiple myeloma, panelists consider disparities in care and share how these barriers are being addressed.
EP. 13: Recap: Experts at Mount Sinai Grapple With Best Practices in Multiple Myeloma
A panel of experts from Mount Sinai examines representative patient cases and reviews treatments in multiple myeloma.
2 Commerce Drive Cranbury, NJ 08512